Omnibus Not Expected To Include Brand-Backed Part D Donut-Hole Change

Although unreleased at press time, the omnibus appropriations bill is not expected to include a measure backed by brand drug companies to lower their share of Medicare Part D coverage-gap costs, congressional staff and drug lobbyists say. Prospects are less certain for a measure to eliminate so-called pass-through pay for biosimilars that hospitals in the 340B drug discount program buy. Senators ended their day of business Wednesday (March 21) without releasing a government spending bill. It's not clear when it...